Division of Epidemiological Investigation Analysis, Bureau of Public Health Emergency Preparedness, Korea Disease Control and Prevention Agency, Cheongju, Korea
Auto-generated profile, based on publicly available information
Mi Yu
Division of Epidemiological Investigation Analysis, Bureau of Public Health Emergency Preparedness, Korea Disease Control and Prevention Agency, Cheongju, Korea
Objectives: On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ritonavir) as a treatment method that could reduce the risk of hospitalization or death for patients with confirmed coronavirus disease 2019 (COVID-19).Methods: From February 6, 2022 to April 2, 2022, the incidence of COVID-19 and the effects of treatment with Paxlovid were analyzed in 2,241 patients and workers at 5 long-term care facilities during the outbreak of the Omicron variant of severe acute respiratory syndrome coronavirus 2 in South Korea.Results: The rate of severe illness or death in the group given Paxlovid was 51% lower than that of the non-Paxlovid group (adjusted risk ratio [aRR], 0.49; 95% confidence interval [CI], 0.24−0.98). Compared to unvaccinated patients, patients who had completed 3 doses of the vaccine had a 71% reduced rate of severe illness or death (aRR, 0.29; 95% CI, 0.13−0.64) and a 65% reduced death rate (aRR, 0.35; 95% CI, 0.15−0.79).Conclusion: Patients given Paxlovid showed a lower rate of severe illness or death and a lower fatality rate than those who did not receive Paxlovid. Patients who received 3 doses of the vaccine had a lower rate of severe illness or death and a lower fatality rate than the unvaccinated group.
Objectives: This study aimed to assess the contact tracing outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-lineages BA.4, BA.5, and BA.2.75 within Republic of Korea, and to generate foundational data for responding to future novel variants.Methods: We conducted investigations and contact tracing for 79 confirmed BA.4 cases, 396 confirmed BA.5 cases, and 152 confirmed BA.2.75 cases. These cases were identified through random sampling of both domestically confirmed and imported cases, with the goal of evaluating the pattern of occurrence and transmissibility.Results: We detected 79 instances of Omicron sub-lineage BA.4 across a span of 46 days, 396 instances of Omicron sub-lineage BA.5 in 46 days, and 152 instances of Omicron sub-lineage BA.2.75 over 62 days. One patient with severe illness was confirmed among the BA.5 cases; however, there were no reports of severe illness in the confirmed BA.4 and BA.2.75 cases. The secondary attack risk among household contacts were 19.6% for BA.4, 27.8% for BA.5, and 24.3% for BA.2.75. No statistically significant difference was found between the Omicron sub-lineages.Conclusion: BA.2.75 did not demonstrate a higher tendency for transmissibility, disease severity, or secondary attack risk within households when compared to BA.4 and BA.5. We will continue to monitor major SARS-CoV-2 variants, and we plan to enhance the disease control and response systems.
31 August 2025 in Osong Public Health and Research Perspectives
Objectives: This study aimed to strengthen the core capabilities of epidemiological investigation and response teams (ERTs) at the Korea Disease Control and Prevention Agency, drawing on lessons learned from the Middle East respiratory syndrome and coronavirus disease 2019 pandemics. The primary objectives were to facilitate rapid and accurate data collection and analysis, improve communication skills, and simulate real-world on-site responses.Methods: The training program was developed using a scenario involving a novel infectious disease from the World Health Organization priority list entering a community. ERTs collected and analyzed epidemiological data and implemented control measures as they addressed the missions of the scenario. Improvement in competencies was assessed through self-evaluation surveys completed before and after training.Results: A total of 49 participants, including disease control officers, epidemic intelligence officers, researchers, and administrative officials, attended the training. Participant satisfaction with the training was high, scoring 6.4 out of 7, and the improvement in competency was statistically significant (pre-training score, 5.2; post-training score, 6.2; p<0.001).Conclusion: Scenario-based training can effectively enhance the capabilities of ERTs. Such training is essential, as emerging and re-emerging infectious diseases can exhibit unpredictable spread and potentially severe impacts. Therefore, developing diverse scenarios and conducting regular training sessions are necessary to improve the capacities of ERTs.